CanSino Biologics said at the Pakistan‑China Business and Investment Summit in
Islamabad it has reached an intent to cooperate with Pakistan's AGP Limited on a
13‑valent pneumococcal conjugate vaccine (PCV13i). The parties will further
explore development and market opportunities for the product in Pakistan.